Fennec Pharmaceuticals Inc - Asset Resilience Ratio
Fennec Pharmaceuticals Inc (FENC) has an Asset Resilience Ratio of 0.00% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Fennec Pharmaceuticals Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2017)
This chart shows how Fennec Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Fennec Pharmaceuticals Inc's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Fennec Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read FENC total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Fennec Pharmaceuticals Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Fennec Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Fennec Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Enliven Therapeutics Inc.
NASDAQ:ELVN |
Biotechnology | 83.46% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.12% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
Annual Asset Resilience Ratio for Fennec Pharmaceuticals Inc (2000–2017)
The table below shows the annual Asset Resilience Ratio data for Fennec Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | $0.00 | $28.40 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $3.97 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $1.02 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $2.37 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $1.75 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $2.37 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $5.35 Million | -- |
| 2005-12-31 | 4.13% | $1.18 Million | $28.45 Million | -12.90pp |
| 2003-12-31 | 17.04% | $7.11 Million | $41.73 Million | -- |
| 2002-12-31 | 0.00% | $0.00 | $25.66 Million | -- |
| 2001-12-31 | 78.75% | $5.37 Million | $6.82 Million | -- |
| 2000-12-31 | 0.00% | $0.00 | $10.46 Million | -- |
About Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has co… Read more